Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Moderna slips
Moderna’s stock is falling. Goldman Sachs says it’s no longer a buy.
Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months.
Moderna Stock Falls After Goldman Downgrade. Vaccine Sales Are a Worry.
Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.
Moderna slips as Goldman Sachs downgrades on revenue outlook
Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of clarity over its revenue outlook. Read more here.
Goldman Sachs Downgrades Moderna (MRNA)
Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (NasdaqGS:MRNA) from Buy to Neutral. Analyst Price Forecast Suggests 57.38% Upside As of January 28, 2025, the average one-year price target for Moderna is $70.
Moderna downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance
Moderna Stock Falls on Vaccine Revenue Concerns
Shares of Moderna Inc. (NASDAQ: MRNA) are down 3.2% in premarket trading after a bear note from Goldman Sachs. The firm lowered its rating on MRNA to "neutral" from "buy," and nearly halved its price target from $99 to $51, citing ongoing vaccine revenue challenges.
S&P 500 Gains and Losses Today: Moderna Stock Plunges After Analyst Downgrade
The S&P 500 fell 0.5% on Wednesday, Jan. 29, as the Federal Reserve held interest rates steady in a move widely expected by the financial markets.
23h
on MSN
Why Moderna (MRNA) Crashed on Wednesday?
We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...
4h
Moderna (MRNA) Receives a Hold from Bernstein
In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...
1d
Moderna Stock Is Sliding Wednesday: Here's Why
Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
Black boxes recovered
Los Angeles wildfire updates
Apologizes for old tweets
Top leaders asked to resign
Cause of death revealed
Recuses self from Act 10 suit
Olympic gold medalist dies
Sexual misconduct accusation
FDA approves painkiller
Asteroid may hit Earth
2 more victims in indictment
'As Tears Go By' singer dies
Michigan priest loses license
Signs education orders
Confirmed interior secretary
Hamas confirms death
Ground stop amid IT outage
Ex-worker admits to theft
Blames DEI for crash
Partners w/ US national labs
DOJ sues to block deal
Shiffrin finishes 10th
Nashville bids for franchise
S3 release date revealed
Weekly jobless claims fall
Ebola outbreak in Uganda
Syria’s transitional pres
Wildfire erupts in NC
Deputy shooting sentence
US economy grew 2.3%
Feedback